NAYA Biosciences, Inc. Common Stock (IVF)
IVF Stock Price Chart
Explore NAYA Biosciences, Inc. Common Stock interactive price chart. Choose custom timeframes to analyze IVF price movements and trends.
IVF Company Profile
Discover essential business fundamentals and corporate details for NAYA Biosciences, Inc. Common Stock (IVF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Healthcare Plans
IPO Date
14 Jan 2025
Employees
33.00
Website
https://www.invobio.comCEO
Steven M. Shum
Description
INVO Fertility, Inc., formerly known as NAYA Biosciences, Inc., is a healthcare services fertility company dedicated to expanding assisted reproductive technology (ART) care. The company focuses on building, acquiring, and operating fertility clinics, including “INVO Centers” offering the intravaginal culture (IVC) procedure enabled by its proprietary INVOcell® medical device. This device allows fertilization and early embryo development to occur in vivo within the woman’s body, providing a more natural, intimate, and affordable alternative to traditional IVF. INVO Fertility operates multiple centers in the U.S. and distributes the INVOcell technology to third-party clinics. The company separated its fertility and oncology businesses in April 2025 to focus exclusively on fertility care.
IVF Financial Timeline
Browse a chronological timeline of NAYA Biosciences, Inc. Common Stock corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 18 May 2026
Upcoming earnings on 17 Nov 2025
Earnings released on 14 Aug 2025
EPS came in at -$7.95 , while revenue for the quarter reached $1.86M , beating expectations by +2.68%.
Stock split effective on 21 Jul 2025
Shares were split 1 : 3 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 20 May 2025
EPS came in at -$37.59 , while revenue for the quarter reached $1.64M , beating expectations by +1.94%.
Earnings released on 30 Apr 2025
EPS came in at -$9.04 falling short of the estimated -$3.50 by -158.29%, while revenue for the quarter reached $1.69M , beating expectations by +12.40%.
IVF Stock Performance
Access detailed IVF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.